Home›Companies›Biotech & Pharma›Ovelle

Ovelle Bio Corp.

Developing human eggs from patients' own cells for women who cannot produce viable eggs.

Updated Nov 11, 2026·Latest SEC filing Jun 10, 2026·Suggest an edit

About Ovelle

Ovelle is a private company based in Dover, Delaware, incorporated in 2024 in Delaware. It has reported $7,000,000 raised in one offering on Form D since June 2026. Its chief executive is Travis Potter.

Funding Rounds (SEC Form D)

First saleFiled with SECAmount soldInvestorsAvg. checkTermsFiling
Jun 2, 2026Jun 10, 2026$7,000,000of $9.2M target1$7.0MEquityRule 506(b)Form D ↗

First sale is the date the first investor in the offering committed to invest. Companies must file Form D within 15 days of that date, so filing dates run later.

Leadership Team

Executive officers and directors listed on Ovelle's Form D filed Jun 10, 2026.

Travis Potter
Travis Potter
Chief Executive Officer
Merrick Pierson Smela
Merrick Pierson Smela
Chief Scientific Officer

Sources

  1. SECOvelle Bio Corp. filing history